Table 4 The Association of Reimbursement Composition and CKD Quality Indicators
Reimbursement Composition | Controlled Hypertension (BP < 130/80) in Patients with CKD and Hypertensiona % or aOR (95% CI) (N = 3028) | p-value | Controlled Diabetes (HbA1c < 7%) in Patients with CKD and Diabetesb % or aOR (95% CI) (N = 579) | p-value | ACEi/ARB Use in Patients with CKD and Hypertension % or aOR (95% CI) (N = 3110) | p-value | Statin Use in Patients Age ≥ 50 with CKD % or aOR (95% CI) (N = 3381) | p-value |
|---|---|---|---|---|---|---|---|---|
Unadjusted Prevalence | ||||||||
 Majority Capitation | 43% | 0.040 | 78% | 0.055 | 45% | 0.994 | 21% | 0.075 |
 Majority FFS | 56% | (ref.) | 59% | (ref.) | 45% | (ref.) | 35% | (ref.) |
 Other Revenue Mix | 57% | 0.829 | 61% | 0.758 | 40% | 0.417 | 31% | 0.557 |
Model 1 | ||||||||
 Majority Capitation | 0.61 (0.34–1.08) | 0.091 | 2.57 (0.93–7.10) | 0.068 | 1.02 (0.67–1.54) | 0.924 | 0.55 (0.21–1.42) | 0.215 |
 Majority FFS (ref.) | 1 | – | 1 | – | 1 | – | 1 | – |
 Other Revenue Mix | 1.12 (0.66–1.90) | 0.667 | 1.35 (0.67–2.74) | 0.401 | 0.88 (0.50–1.57) | 0.671 | 0.99 (0.58–1.69) | 0.957 |
Model 2 | ||||||||
 Majority Capitation | 0.65 (0.38–1.11) | 0.113 | 2.87 (1.02–8.06) | 0.046 | 0.77 (0.45–1.32) | 0.339 | 0.75 (0.40–1.38) | 0.350 |
 Majority FFS (ref.) | 1 | – | 1 | – | 1 | – | 1 | – |
 Other Revenue Mix | 1.07 (0.62–1.87) | 0.804 | 1.49 (0.74–3.00) | 0.260 | 0.91 (0.50–1.63) | 0.744 | 0.98 (0.59–1.64) | 0.948 |